Market Signal Briefing

Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Pacific Empire Minerals Corp. (TSXV: PEMC) ("Pacific Empire", "PEMC" or the "Company"), a copper-gold explorer based in British Columbia, is pleased to provide shareholders with a year-end corporate update summarizing key milestones achieved during 2025 and outlining its strategic priorities for 2026. During the year, the Company completed a six-hole diamond drilling program at its Trident Project, advanced its long-term exploration strategy, and continued to execute on a mineral systems-based approach that has guided the assembly of its extensive land position over more than a decade.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

MIAMI--(BUSINESS WIRE)--Element Solutions Inc (NYSE:ESI) (the “Company” or “ESI”), a global and diversified specialty chemical technology company, announced today that it has completed its previously announced acquisition of EFC Gases & Advanced Materials (“EFC”). EFC will operate as a standalone business unit reported within the Company’s newly renamed “Specialties Segment” which was heretofore the “Industrial & Specialty Segment.”

Chief Executive Officer Benjamin Gliklich said, “We are thrilled to welcome EFC to the Element Solutions family of businesses. Their solutions-orientation, team culture and go-to market approach fit seamlessly with our company, while this acquisition brings high value, differentiated capabilities in specialty and rare gases together with advanced materials and introduces attractive new growth vectors in semiconductor manufacturing, electrical transmission infrastructure, and space applications to ESI. EFC will join our newly formed ‘Specialties’ segment, comprised of businesses focused on niche, high-value markets with demanding customer qualification requirements and an emphasis on value-added technical service which together create high-quality recurring revenue streams. We expect the segment to grow in the mid-single digits with adjusted EBITDA margins in excess of 20% and a durable cash flow profile. Our portfolio evolution over the past several years has significantly improved our overall business quality from a growth and profitability perspective as is quite evident in this new ‘Specialties’ segment.”

About Element Solutions Inc

Element Solutions Inc is a leading global specialty chemical technology company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. Developed in multi-step technological processes, these innovative solutions enable customers' manufacturing processes in several key industries, including consumer electronics, power electronics, semiconductor fabrication, communications and data storage infrastructure, automotive systems, industrial surface finishing, and offshore energy.

More information about the Company is available at www.elementsolutionsinc.com.

Forward-looking Statements

This press release contains forward-looking statements, including, but not limited to, statements relating to the benefits of the EFC acquisition and the Company’s expectations with respect to its new Specialties Segment’s growth, adjusted EBITDA and cash flow. These statements are based on management's estimates and assumptions with respect to financial performance and future events, and are believed to be reasonable, though are inherently difficult to predict. Actual results could differ materially from those projected as a result of certain factors including, without limitation, market and other general economic conditions, the Company’s perception of future availability of financing as well as factors included in its periodic and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

More News From Element Solutions Inc

Back to Newsroom

LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against agilon health, inc. (“Agilon” or “the Company”) (NYSE: AGL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of AGL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 26, 2025 to August 4, 2025

DEADLINE: March 2, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Agilon’s 2026 guidance was not attainable, which the Company knew at the time it communicated with investors. The Company overstated the impact of its “strategic actions” to lessen risk. Based on these facts, Agilon’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality

January 05, 2026 07:30 ET

 | Source:

Medicus Pharma Ltd

PHILADELPHIA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco.

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion programs.

Biotech Showcase Presentation Details

Presentation Date:Tuesday, January 13, 2026Time:10:00 a.m. Pacific timeLocation:Yosemite A (Ballroom Level), Hilton San Francisco – Union Square   The presentation will be webcast live and can be accessed here or from the company's website. The webcast will be archived and available for replay after the presentation.

Dr. Bokhari and Medicus executives will be available for one-on-one meetings with institutional investors and prospective partners registered for the conference through the partneringONE portal of the event.

Strategic Focus: Phase 2 De-Risking and Partnering

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies that are best positioned to conduct late-stage development and commercialization.

As data matures across its programs, the Company aims to assemble decision-grade clinical, regulatory, and operational data packages aligned with this out-licensing strategy.

SkinJect™ Phase 2 Program: Execution Milestones Achieved

Medicus continues to advance SkinJect™, its novel, proprietary doxorubicin containing dissolvable microneedle array (D-MNA) platform, designed to non-invasively treat basal cell carcinoma (BCC) of the skin.

In December 2025, the Company completed enrollment of 90 patients in its randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study (SKNJCT-003) across nine clinical sites in the United States. The study is designed to evaluate the safety, tolerability, and clinical efficacy of SkinJect™.

The Company expects to report topline decision grade Phase 2 results in the first quarter of 2026 and to pursue an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2026.

Previously disclosed positively trending interim findings demonstrated greater than 60% clinical clearance in an exploratory analysis conducted after more than 50% of patients of the then-targeted 60 patients in the study had been randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.

Regulatory and Geographic Expansion Supports De-Risking Strategy

Medicus has expanded the clinical and regulatory footprint of SkinJect™ to support development and partnering readiness:

United States: Phase 2 enrollment completed for SKNJCT-003United Kingdom: Full regulatory and ethics approvals received from the MHRA, HRA, and WREC to expand SKNJCT-003United Arab Emirates: First patient dosed in SKNJCT-004, a Phase 2 study conducted at six sites with Cleveland Clinic Abu Dhabi as principal investigator
In September 2025, the FDA provided positive feedback following a Type C meeting, supporting the potential use of the 505(b)(2) regulatory pathway for SkinJect™.

Regulatory Optionality: FDA Commissioner’s National Priority Voucher (CNPV)

In November 2025, Medicus applied to the U.S. Food and Drug Administration (FDA) seeking eligibility for the FDA Commissioner’s National Priority Voucher (CNPV) program for SkinJect™.

If granted, the CNPV could provide Medicus with a voucher intended to accelerate FDA review timelines for a future new drug application, which the Company may utilize as part of a strategic partnering or licensing transaction. There can be no assurance that the application will be approved or that a voucher will be granted.

The Company believes that SkinJect™’s non-invasive approach to treating basal cell carcinoma and its potential public-health impact support consideration under the program. Medicus continues to advance its regulatory strategy in parallel with clinical development and partnering preparation.

AI-Enabled Clinical Development: Reliant AI Engagement

In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences, to collaborate on the development of an AI-driven clinical data analytics platform.

Subject to execution of definitive agreements, the platform is expected to support capital-efficient clinical development through data-driven dynamic clinical-site selection, patient stratification, and enrollment forecasting. The initial phase of the collaboration is expected to support an upcoming Teverelix clinical study planned for 2026, with potential expansion into later-stage development programs in collaboration with a strategic partner. There can be no assurance that a definitive agreement will be executed with Reliant AI Inc. or that the proposed collaboration will proceed as contemplated.

Skinject Platform Expansion: Helix Nanotechnologies MoU:

The Company is exploring co-development of thermostable infectious disease vaccines combining HelixNano’s proprietary mRNA technology with Medicus microneedle array delivery platform.

Pipeline Expansion—Acquisition of Antev

With the acquisition of Antev Limited (“Antev”) in August 2025, a UK-based clinical stage biotech company, Medicus added Teverelix, a next generation GnRH antagonist targeting advanced prostate cancer patients with elevated cardiovascular risk and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Patient Access and Advocacy---Gorlin Syndrome Alliance Collaboration

In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA), under physician supervision. The initiative aims to establish a framework for expanded access while generating real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect™ in this rare disease population.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
[email protected]

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
[email protected]

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the "MoU") with Helix Nanotechnologies, Inc. ("HelixNano"), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk. 

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients

In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect™ in this rare disease population.

In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards.

In December 2025, the Company announced that it has successfully completed enrolment of ninety (90) patients in the United States for phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026.

In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences, to collaborate on the development of an AI-driven clinical data analytics platform. Subject to execution of definitive agreements, the platform is expected to support capital-efficient clinical development through data-driven dynamic clinical-site selection, patient stratification, and enrollment forecasting. The initial phase of the collaboration is expected to support an upcoming Teverelix clinical study planned for 2026, with potential expansion into later-stage development programs in collaboration with a strategic partner.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company’s submission for approval in the FDA Commissioner's National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company’s expectation to release topline results for SKNJCT-003 in the first quarter of 2026 and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", “on track”, “aim”, "might", "will", "will likely result", “could,” “designed,” "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CNQ, CME, TPL, ODFL, RTX, HD, UNP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

January 05, 2026 07:30 ET

 | Source:

Copperhead Resources Inc.

Vancouver, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Copperhead Resources Inc. (CSE: CUH) ("Copperhead" or the "Company") announces that Kevin Zhou has resigned as an officer of the Company.  The Company thanks Mr. Zhou for his contributions and service.

The Company is also pleased to announce that Denise Lok, Chief Financial Officer and a director of the Company, has been appointed Corporate Secretary and that James A. Deckelman has been appointed Chief Executive Officer.

Mr. Deckelman is an exploration and energy executive with over 25 years of international oil and gas experience in resource discovery, operations leadership, and corporate strategy. He has held executive and technical leadership roles with major global energy companies, including ConocoPhillips, BP and Talisman, where he contributed to the discovery and advancement of significant resource portfolios across the Americas, Africa and the Middle East. Mr. Deckelman is currently President of Mayfair Energy Ventures, LLC. He served as Chief Executive Officer and Director of BluEnergies Ltd. (TSXV: BLU) in 2024 and 2025, and Chief Exploration Officer for GeoPark (NYSE: GPRK), a Latin America producer and explorer.

Mr. Deckelman holds a Master’s degree in Geology from Utah State University and a Bachelor of Arts degree in Geology from Miami University. He has authored numerous technical publications in the field of petroleum geology and exploration strategy.

About Copperhead Resources Inc.

Copperhead Resources Inc. is a mineral resource company engaged in the business of acquiring and exploring mineral resource properties, with a focus on critical elements and precious metals. The Company holds an option to acquire a 100% interest in the Twilite Gold Project located in the Central Newfoundland Gold Belt. From time to time the Company may also evaluate and acquire other mineral properties of merit, containing a variety of metals and minerals and located in a variety of geographical jurisdictions.

ON BEHALF OF THE BOARD

“James A. Deckelman”
James A. Deckelman, Chief Executive Officer

For further information about Copperhead, please contact:

James A. Deckelman
Chief Executive Officer
Copperhead Resources Inc.
Phone: 1-281-467-1279
Email: [email protected]

The CSE does not accept responsibility for the adequacy or accuracy of this release.

January 05, 2026 07:30 ET

 | Source:

Enviri

Tom Vadaketh will retire following the Clean Earth sale and spin-off of New Enviri that is expected mid-yearFormer Enviri CFO, Pete Minan, will bring finance industry experience and deep understanding of Enviri and its Harsco Environmental and Rail businesses PHILADELPHIA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enviri Corporation (NYSE: NVRI) (“Enviri,” or the “Company”) today announced the retirement of Chief Financial Officer (“CFO”) Tom Vadaketh and the planned appointment of Pete Minan as CFO of New Enviri concurrently with the planned spin-off into a standalone publicly traded company. Minan will serve as a consultant to the Company as New Enviri prepares for the spin-off.

“We are grateful for Tom’s impact on the organization and the strength he has brought to our finance function, especially throughout our successful strategic alternatives initiative,” said Enviri Chairman and CEO Nick Grasberger. “Tom is guiding the Company through a time of significant change, providing steady leadership, technical expertise, and disciplined financial stewardship, and leaving a legacy of financial discipline, increased engagement, and professional development for our finance team. He has positioned the Company well for its next chapter, and we wish him well in his retirement.”

As previously announced, the spin-off of New Enviri will be effected in connection with the Company’s sale of Clean Earth to Veolia Environnement SA. The Clean Earth sale remains on track for completion in mid-2026, and Tom Vadaketh will remain Chief Financial Officer of Enviri until the transactions are completed.

“I am pleased to welcome Pete back as the CFO of New Enviri as we position Harsco Environmental and Rail for success and build a company that creates value for shareholders and customers,” said Russell Hochman, Enviri President and Chief Operating Officer and CEO designate of New Enviri. “Pete’s financial acumen, deep understanding of our businesses, and strategic mindset make him the ideal financial leader for New Enviri.”

“Harsco Environmental and Rail are market-leading providers of innovative solutions for the steel and rail industries, and they have a significant opportunity to drive enhanced financial performance and sustainable growth under their new company structure,” said Mr. Minan. “I am eager to hit the ground running and look forward to partnering with Russell and the leadership team to ensure a successful and seamless separation and to create value for our New Enviri shareholders.”

Additional members of New Enviri’s leadership team, as well as its Board of Directors, will be announced at a later date. The Company expects to file a Form 10 registration statement for New Enviri with the U.S. Securities and Exchange Commission in connection with the New Enviri spin-off, which remains subject to satisfaction of customary closing conditions.

About Enviri
Enviri is transforming the world to green, as a trusted global leader in providing a broad range of environmental services and related innovative solutions. The Company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their most complex environmental challenges and to achieve their sustainability goals. Enviri is based in Philadelphia, Pennsylvania and operates in more than 150 locations in over 30 countries. Additional information can be found at www.enviri.com.

About Pete Minan
Pete Minan joined Harsco Corporation as CFO in October 2014 and served in the role for seven years until his retirement in October 2021. He returned to Enviri in an interim basis as CFO in August 2022, serving through October 2023 and overseeing the Company’s global financial strategy. Prior to joining the Company, Mr. Minan was a Senior Partner at KPMG, where he developed an extensive background in global financial management during nearly 30 years at the firm. Mr. Minan most recently served as an adjunct Professor of Finance at Drexel University. Mr. Minan holds a B.S. from the University of Virginia and is a Certified Public Accountant.

Additional Information and Where to Find It

In connection with the proposed sale of Clean Earth and the contemplated spin-off of New Enviri, the Company and New Enviri will be filing documents with the SEC, including preliminary and definitive proxy statements of the Company relating to the proposed transaction and a registration statement relating to the shares of New Enviri. The definitive proxy statement will be mailed to the Company's shareholders in connection with the proposed acquisition. This communication is not a substitute for the proxy statement, the registration statement or any other document that may be filed by the Company or New Enviri with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION. Any vote in respect of resolutions to be proposed at the Company's shareholder meeting to approve the proposed transaction should be made only on the basis of the information contained in the Company's proxy statement and documents incorporated by reference therein. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's website at www.sec.gov or on the Company's website at www.enviri.com.

Participants in Solicitation

The Company, its directors, and certain of its respective executive officers may be deemed to be participants in the solicitation of proxies from shareholders of the Company in connection with the proposed transaction under the rules of the SEC. Information about the interests of the directors and executive officers of the Company and other persons who may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the proxy statement to be filed with the SEC by the Company related to the proposed transaction. Information about the directors and executive officers of the Company and their ownership of shares of Company common stock and other securities of the Company can be found in the sections entitled “Non-Employee Director Compensation”, “Share Ownership of Directors, Management and Certain Beneficial Owners”, “Compensation Discussion & Analysis”, “Discussion and Analysis of 2024 Compensation”, “Termination or Change of Control Arrangements”, “Equity Compensation Plan Information as of December 31, 2024” included in the Company’s proxy statement in connection with its 2025 Annual Meeting of Stockholders, filed with the SEC on March 12, 2025; in the Form 3 and Form 4 statements of beneficial ownership and statements of changes in beneficial ownership filed with the SEC by the Company’s directors and executive officers; and in other documents subsequently filed by the Company with the SEC. Investors and security holders may obtain free copies of these documents and other related documents filed with the SEC at the SEC's website at www.sec.gov or on the Company's website at www.enviri.com.

PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT.

To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Transaction strengthens balance sheet and liquidity with cash proceeds of $1.15 billion before customary closing adjustments
HOUSTON and LONDON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR, “the Company”), an energy technology company, announced Monday the successful closing of the sale of its Precision Sensors & Instrumentation (PSI) product line to Crane Company (NYSE: CR, “Crane”). PSI includes the Druck, Panametrics and Reuter-Stokes brands, and the Company had announced the divesture in July 2025.

With the recently announced formation of a joint venture for its surface pressure control product line, these transactions represent an important milestone in Baker Hughes’ value-creation strategy, reinforcing the Company’s commitment to disciplined portfolio management, operational execution and capital efficiency. The transactions enhance earnings and cash flow durability, enable the redeployment of capital toward higher-return opportunities, and provide cash proceeds to further strengthen the balance sheet, all within a rigorous, returns-focused approach to capital allocation.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Media Relations

Adrienne M. Lynch
+1 713-906-8407
[email protected] 

Investor Relations

Chase Mulvehill
+1 346-297-2561
[email protected] 

, /PRNewswire/ -- Ceragon (NASDAQ: CRNT), a leading solutions provider of end-to-end wireless connectivity, announces that management will participate in the 28th Annual Needham Growth Conference being held on January 13-14 at the Lotte NY Palace Hotel. A fireside chat with management will be held at 10:15am ET on Wednesday, January 14. Investors can listen to the live webcast of the fireside chat here, and a replay will be available via the same link and on the Company's website following the conference.

Additionally, management will be available for 1x1 meetings throughout the conference. Investors who wish to request a 1x1 meeting should contact their Needham & Company representative.

About Ceragon

Ceragon (NASDAQ: CRNT) is the global innovator and leading solutions provider of end-to-end wireless connectivity, specializing in transport, access, and AI-powered managed & professional services. Through our commitment to excellence, we empower customers to elevate operational efficiency and enrich the quality of experience for their end users.

Our customers include service providers, utilities, public safety organizations, government agencies, energy companies, and more, who rely on our wireless expertise and cutting-edge solutions for 5G & 4G broadband wireless connectivity, mission-critical services, and an array of applications that harness our ultra-high reliability and speed. Ceragon solutions are deployed by more than 600 service providers, as well as more than 1,600 private network owners, in more than 130 countries. Through our innovative, end-to-end solutions, covering hardware, software, and managed & professional services, we enable our customers to embrace the future of wireless technology with confidence, shaping the next generation of connectivity and service delivery. Ceragon delivers extremely reliable, fast to deploy, high-capacity wireless solutions for a wide range of communication network use cases, optimized to lower TCO through minimal use of spectrum, power, real estate, and labor resources - driving simple, quick, and cost-effective network modernization and positioning Ceragon as a leading solutions provider for the "connectivity everywhere" era.

For more information please visit: www.ceragon.com.

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON® is a trademark of Ceragon, registered in various countries. Other names mentioned are owned by their respective holders.

Investor Contact:

Rob Fink
FNK IR
1+646-809-4048

Joey Delahoussaye
FNK IR
1+312-809-1087
[email protected]

Logo - https://mma.prnewswire.com/media/1704355/Ceragon_Networks_Ltd_Logo.jpg 

SOURCE Ceragon Networks Ltd.

Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Chesapeake Gold Corp. (TSXV: CKG) (OTCQX: CHPGF) ("Chesapeake" or the "Company") announces the grant of stock options to Mr. Rajesh Vyas in relation to his appointment as Chief Financial Officer (previously announced by news release dated January 2, 2026) under its Stock Option Plan to purchase an aggregate of 100,000 common shares of the Company at an exercise price of C$4.24 per share for a five-year term expiring January 5, 2031. The options will vest and be exercisable on the basis of 25% annually, commencing January 5, 2027, the first anniversary of the date of the grant.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Chesapeake

Chesapeake Gold Corp's flagship asset is the Metates Project ("Metates") located in Durango State, Mexico. Metates hosts one of the largest undeveloped gold-silver deposits in the Americas1 with over 16.77 million ounces of gold at 0.57 grams per tonne (g/t) and 423.2 million ounces of silver at 14.3 g/t within 921.2 million tonnes in the Measured and Indicated Mineral Resource category and a further 2.13 million ounces of gold at 0.47 g/t and 59.0 million ounces of silver at 13.2 g/t within 139.5 million tonnes in the Inferred Mineral Resource category. See the technical report titled "Metates Sulphide Heap Leach Project Phase I" dated January 13, 2023, and news release dated February 22, 2023.

1 Mexico's biggest undeveloped gold deposits. Bnamericas. Published Tuesday, November 24, 2020.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279437

Source: Chesapeake Gold Corp.

Realty Income and Energy Transfer are reliable income plays in this wobbly market.

Many dividend stocks slumped in 2022 and 2023 as rising interest rates drove investors toward higher-yielding CDs, bonds, and T-bills. However, the Federal Reserve reduced its benchmark rates six times in 2024 and 2025 as inflation cooled off.

As those rates declined, high-yield stocks became more appealing again. Let's take a closer look at two of my personal favorites -- Realty Income (O +1.67%) and Energy Transfer (ET +0.61%) -- and why they're still rock-solid stocks for income-oriented investors.

Image source: Getty Images.

Realty Income
Realty Income is one of the world's largest equity real estate investment trusts (REITs). It buys up properties, leases them out, and splits its rental income with its tenants. As a triple-net lease REIT, its tenants are responsible for covering their own maintenance fees, insurance, and property taxes. It also must pay out at least 90% of its taxable income as dividends to maintain a lower tax rate.

Realty owns more than 15,500 commercial properties across the U.S. and Europe. It primarily leases its properties to recession-resistant retailers, including drugstores, convenience stores, and discount stores. Its largest tenants are 7-Eleven (3.3% of its annualized base rent), Dollar General (3.2%), and Walgreens (3.1%).

Today's Change

(

1.67

%) $

0.94

Current Price

$

57.31

Some of its tenants struggled with store closures in recent years, but its stronger retail tenants opened more stores to offset that pressure. Its occupancy rate has remained above 96% since its IPO in 1994, and this ratio has held steady year over year at 98.7% in the third quarter of 2025.

Realty's resilient portfolio of income-generating properties enables it to pay monthly dividends, and it has raised its payout 132 times since its public debut. It expects its adjusted funds from operations (AFFO) per share to rise from $4.19 in 2024 to $4.25-$4.27 in 2025. That should easily cover its forward dividend rate of $3.22, which translates to a substantial forward yield of 5.6%.

At $57, Realty's stock still appears to be a bargain at 13 times its estimated AFFO per share for 2025. Its high yield and low valuation should limit its downside in this choppy market, and its high dividends should draw in more income investors as interest rates decline.

Energy Transfer
Energy Transfer, one of the top midstream companies in America, operates over 140,000 miles of pipeline in 44 states. It provides delivery, storage, and terminalizing services for natural gas, liquefied natural gas (LNG), natural gas liquids, crude oil, and other refined products.

Energy Transfer charges upstream extraction companies and downstream refining companies fees to use its infrastructure. The midstream "toll road" model is well-insulated from volatile natural gas and crude oil price swings, as it merely requires these resources to keep flowing through its pipelines to generate stable revenues and profits.

Today's Change

(

0.61

%) $

0.10

Current Price

$

16.59

Energy Transfer structures its business as a master limited partnership (MLP), which combines the tax advantages of a private partnership with the liquidity of a publicly traded stock. Yet it remains vulnerable to tariffs, which drive up its material, labor, and construction costs, and high interest rates, which increase its interest expenses and make it more expensive to expand its pipelines.

However, its adjusted distributable cash flow (DCF) -- which funds its annual distributions -- still increased from $5.74 billion in 2020 to $8.36 billion in 2024. During the same period, its yearly distributions rose from $2.47 billion to $4.39 billion. Its acquisitions of industry peers, the expansion of its Permian Basin operations, and the rising demand for LNG exports drove that growth, even as the pandemic and other macroeconomic headwinds rattled the global economy.

For 2025, analysts expect Energy Transfer's earnings per unit (EPU) to rise 4% to $1.34 -- covering its forward distribution rate of $1.33 per share -- which equals a forward yield of 8%. A portion of that yield comes from a tax-efficient return of capital, while its adjusted DCF covers the rest. At $17, it still looks undervalued at 13 times its projected EPU for 2025 -- so it's still a great choice for value-oriented income investors.

Australian payment firm Airwallex said on Monday it will invest around 200 million euros ($233.64 million) over the next five years in its Netherlands operations, marking a major European expansion as it shifts from its Asia-Pacific base.

For Immediate ReleasesChicago, IL – January 5, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amazon.com, Inc. (AMZN - Free Report) , Palantir Technologies Inc. (PLTR - Free Report) , TotalEnergies SE (TTE - Free Report) and MIND Technology, Inc. (MIND - Free Report) .

 Here are highlights from Monday’s Analyst Blog:Top Research Reports for Amazon, Palantir and TotalEnergiesThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Palantir Technologies Inc. and TotalEnergies SE, as well as a micro-cap stock MIND Technology, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Odds for a "January Effect" in 2026?

Today's Featured Research ReportsAmazon.com’s shares have outperformed the Zacks Internet - Commerce industry over the past six months (+4.5% vs. +2.4%). The company’s international expansion and diversification across e-commerce, AWS cloud services, advertising, and streaming create multiple revenue streams while reducing concentration risk.

Management's Q4 2025 guidance projects net sales of $206-$213 billion with operating income between $21-$26 billion, reflecting operational efficiency gains. AI integration across operations enhances personalization, logistics and AWS offerings, strengthening competitive positioning. The Zacks analyst expect 2025 net sales to grow 10.6% from 2024.

However, substantial capital expenditure requirements for AI infrastructure and data centers strain financial resources and compress margins. The company's expanding debt burden reduces financial flexibility amid rising interest rates. Intensifying competition from Walmart, Microsoft Azure and Google Cloud is an overhang.

(You can read the full research report on Amazon.com here >>>)

Shares of Palantir have outperformed the Zacks Internet - Software industry over the past six months (+32.3% vs. -6.5%). The company’s AI strategy, driven by Foundry, Gotham, and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. Notable defense projects, like Open DAGIR and AIP boot camps for commercial clients, boost customer acquisition.

With $5.4 billion in cash, no debt, and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues, and increased investor visibility. Meanwhile, PLTR's reluctance to pay dividends is a green flag for dividend-seeking investors.

Intense competition from tech giants and rising costs amidst a rapidly evolving AI landscape and an elevated valuation challenge its appeal. Palantir shares have gained 122.5% in a year, and we have a neutral rating on it in anticipation of a correction.

(You can read the full research report on Palantir here >>>)

TotalEnergies’shares have outperformed the Zacks Oil and Gas - Refining and Marketing industry over the past six months (+5.9% vs. +1.7%). The company is gaining from contributions coming from startups, acquired assets, well-spread LNG assets and upstream assets located in the new hydrocarbon-producing regions. Contributions from multi-energy assets spread across the globe boost its earnings.

TotalEnergies’ free cash flow allows it to increase shareholders’ value. Cost reduction initiatives will boost margins and the company aims to generate 15-20% of sales from low-carbon business by 2040. TotalEnergies is investing in clean power generation and lowering emissions.

Yet TotalEnergies operates multiple assets globally, and in some regions, production might be impacted due to security concerns. It remains exposed to acquisition-related risks as these assets contribute a sizable volume to production.

(You can read the full research report on TotalEnergies here >>>)

Shares of MIND Technology have gained +11.4% over the past six months against the Zacks Technology Services industry’s gain of +15.4%. This microcap company with a market capitalization of $79.44 million shows improving near-term visibility, with a $9.5 million seismic contract secured in December 2025, highlighting product demand. Recent expansion of its Huntsville facility supports higher-margin throughput and positions the firm for complex project growth.

New capital flexibility via a $25 million ATM offering and $4 million repurchase program enhances strategic agility. MIND benefits from exposure to a resilient global marine seismic market and operates a globally diversified footprint, aiding responsiveness and contract wins.

However, declining revenue and backlog highlight demand volatility, and a growing reliance on aftermarket sales may limit long-term upside. Profitability is pressured by modestly rising operating expenses. Despite this, shares are up 13.7% in the past year, and valuation remains attractive at 1.1X EV/Sales and 7.87X EV/EBITDA, well below peers.

(You can read the full research report on MIND Technology here >>>)

Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]                                     

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

For Immediate ReleasesChicago, IL – January 5, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caterpillar Inc. (CAT - Free Report) , Komatsu (KMTUY - Free Report) and Terex Corp. (TEX - Free Report) ,

Here are highlights from Monday’s Analyst Blog:After a +58% Run in 2025, Is CAT Stock Still a Buy in 2026?Caterpillar Inc. shares have delivered a strong 57.9% in the past year, outpacing the manufacturing - construction and mining industry's 55.9% growth. In contrast, the Zacks Industrial Products sector and the S&P 500 posted more modest gains of 5.5% and 18.7%, respectively.

CAT has also outperformed its peers, Komatsu and Terex Corp., as shown in the chart below.

From a technical standpoint, Caterpillar has been trading above its 200-day simple moving average (SMA) since May last year and remains above its 50-day SMA, signaling sustained upward momentum. This price action reflects investor confidence in CAT’s operating performance, balance sheet strength and long-term growth prospects.

CAT Returns to Revenue Growth in Q3, Posts Record BacklogCaterpillar’s improving fundamentals supported its stock performance in 2025. In the third quarter of 2025, the company posted revenues of approximately $17.6 billion, marking its highest quarterly number on record. Revenues were up 9.5% as a 10% increase in sales volume and a favorable currency impact of 1% were offset by an unfavorable price realization of 1.3%.

Broad-based volume gains helped CAT break the streak of six straight quarters of revenue declines. Backlog also strengthened, rising sequentially by $2.4 billion to a record $39.9 billion, providing solid visibility into future revenues.

CAT now expects 2025 revenues to be “modestly” higher compared with 2024, an improvement from its prior projection of “slightly” higher revenues.

Caterpillar Shows Improving Earnings ResilienceCost of sales climbed 16% in the third quarter due to higher manufacturing costs and tariff impacts, resulting in a 4% year-over-year decline in earnings to $4.95 per share. Encouragingly, the pace of earnings decline has slowed meaningfully from the 27% drop in the first quarter of 2025 to a 15.7% decline in the second quarter and the 4% decline reported in the third quarter, highlighting improving operational momentum.

Peers continue to face more pronounced challenges. Terex has seen seven straight quarters of negative organic growth in its Material Processing segment due to subdued demand. The company expects this trend to reflect on its 2025 results. Terex’s Aerial segment has seen eight straight quarters of negative organic growth.

Komatsu experienced a decline in volumes within its Construction, Mining & Utility Equipment segment during fiscal 2024, which persisted in the first half of fiscal 2025 (ended Sept. 30, 2025). Komatsu expects demand for construction, mining and utility equipment in fiscal 2025 to remain flat compared with the fiscal 2024 level.

Earnings Estimates Suggest CAT Will Rebound in 2026Earnings estimates for Caterpillar for both 2025 and 2026 have moved up over the past 60 days. The Zacks Consensus Estimate for CAT’s 2025 earnings indicates a year-over-year decline of 15.57%, with revenues suggesting growth of 2.29%. The earnings estimates for 2026 suggest 18.95% growth, with revenues rising 8.30%.

Caterpillar Stock Trades at a PremiumCaterpillar is currently trading at a forward 12-month price/earnings (P/E) ratio of 30.96X compared with the industry average of 28.51X. Meanwhile, Komatsu and Terex Corp. are trading below the industry at 12.02X and 10.83X, respectively.

CAT Delivers Attractive ReturnsCaterpillar’s return on equity (ROE) is 47.16%, higher than the industry’s average of 46.52%. It is also higher than the S&P 500’s return of 32.48%. Meanwhile, Komatsu offers an ROE of 12.41% and Terex an ROE of 15.93%.

Caterpillar Positioned for Long-Term GrowthOver the long term, Caterpillar stands to benefit from increased infrastructure spending under the U.S. Infrastructure Investment and Jobs Act. The global energy transition is also expected to lift demand for critical minerals, strengthening the outlook for CAT’s mining equipment portfolio. Adoption of Caterpillar’s autonomous mining fleet continues to accelerate, driven by productivity, safety and cost-efficiency benefits.

As technology companies establish data centers globally to support their generative AI applications, Caterpillar is witnessing robust order levels for reciprocating engines for data centers. The company is planning to double its output with a multi-year capital investment. Caterpillar recently entered into a long-term strategic collaboration with Hunt Energy Company, L.P., to meet the surging power needs of data centers. The first project is planned for Texas and is expected to serve as the launchpad for a multi-year program to deliver up to one gigawatt of power generation capacity for data centers across North America.

Caterpillar has also entered into an agreement to develop advanced energy optimization solutions for data centers. This collaboration focuses on integrating Vertiv's power distribution and cooling portfolio with Caterpillar’s know-how in power generation and CCHP (Combined Cooling, Heat and Power). CAT’s efforts to grow its aftermarket parts and service-related revenues, which generate high margins, will also aid growth.

How Should Investors Approach CAT Stock Now?Caterpillar’s premium valuation appears justified given its return to revenue growth, record backlog, improving earnings trajectory and relative strength versus peers in a challenging macro environment. The company’s strong long-term growth drivers, anchored by infrastructure investment, energy-transition trends, data center expansion and a growing high-margin services business, provide clear visibility into future earnings power.

With earnings expected to rebound meaningfully in 2026 and growth prospects strengthening, CAT’s Zacks Rank #2 (Buy) further reinforces our positive outlook.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]                                     

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

Foxconn, a major partner for Nvidia, has reported a 22% surge in revenues in the final quarter of 2025, as tech firms continue to ramp up spending on AI infrastructure.

Also known as Hon Hai, Foxconn reported revenues of 2.6 trillion Taiwan dollars ($83 billion) in the quarter up to December, as its components and cloud businesses demonstrated strong growth, the company said.

The figure tops analyst expectations of NT$2.4 trillion ($77 billion), according to LSEG estimates.

Foxconn is the world's largest contract electronics manufacturer and makes the servers that hold chips in data centers. It also assembles Apple's iPhone.

The company has emerged as a key player in AI as companies race to build out infrastructure for the technology. Its share price rose 25% across 2025, following a 76% uptick over the previous year.

watch now

"Revenue in the fourth quarter of 2025 achieved strong growth both QoQ and YoY, exceeding our expectation of significant growth, causing a high base for the first quarter," the company said in a statement.

Foxconn signed a partnership with OpenAI in November to collaborate on designs for next-generation AI infrastructure hardware.

In May, it was announced that the company would partner with Nvidia and the Taiwanese government to provide infrastructure to a major AI factory in Taiwan.

also announced in July that it was taking a stake in data center construction company TECO Electric & Machinery Co.

Foxconn said it expected earnings to be near the upper end of the past five-year range thanks to the continued rise in AI rack shipments, despite entering the "traditional off-season" for ICT products in the first quarter of the year.

A bullish note from Goldman Sachs analysts on Taiwan Semiconductor Manufacturing Co. lifted shares of the global chip manufacturer in early trade on Monday.

January 05, 2026 06:30 ET

 | Source:

Parsons Services Company

CHANTILLY, Va., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was recently awarded a ten-year, $392 million single-award contract by a Federal customer. This represents new work for the company and leverages the company’s biometrics and network engineering capabilities.

Parsons offers advanced biometrics and identity management solutions, combining hardware, software, and integration expertise to support federal, defense, and law enforcement missions. The company has delivered over 3,500 mobile biometrics solutions that provide cutting-edge tools to collect and analyze biometric data in real-time, enabling faster identity verification and improved threat detection during critical missions.

For more information about Parsons' identity solutions, visit parsons.com/identity-management-and-biometrics/.

About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Forward-Looking Statements:
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive, and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Registration Statement on Form S-1 and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this presentation that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so in connection with our ongoing requirements under federal securities laws.

Media Contact:
Bernadette Miller
+1 980.253.9781
[email protected]

Investor Relations Contact:
Dave Spille
+1 703.775.6191
[email protected]

January 05, 2026 06:30 ET

 | Source:

Neumora Therapeutics, Inc.

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect 

NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety

NMRA-511 demonstrated a favorable tolerability and safety profile

Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026

Company to host conference call today at 8:00 am ET

WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer’s disease (AD) agitation. NMRA-511, an oral, highly potent, brain-penetrant and selective antagonist of the vasopressin 1a receptor (V1aR) met the goal of the Phase 1b study, demonstrating a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable tolerability and safety profile with no reports of somnolence or sedation.

“The goal of this signal-seeking study was to investigate the clinical potential of NMRA-511 in AD agitation and to identify a clinical effect size to inform further development. It has achieved that goal, demonstrating a clinically meaningful and robust effect in a broad patient population. We are encouraged by these data, which demonstrate a clear clinical effect that NMRA-511 meaningfully improves agitation symptoms among people with AD agitation, and has an unsurpassed effect size among patients with higher levels of baseline anxiety, with a favorable safety and tolerability profile” said Bill Aurora, Pharm.D., chief operating and development officer, Neumora. “Anxiety is often an underlying symptom that is present early in the AD agitation disease course, and there is an unmet need for tolerable therapies that can reduce agitation and anxiety symptoms. We look forward to advancing the program and exploring higher doses of NMRA-511. Our deepest thanks go to the patients who participated in this study, their families, the dedicated investigators and others who contributed to the important work of developing better treatments for this devastating condition.”

“AD agitation is a common and distressing symptom in Alzheimer's dementia that can significantly impact the quality of life for both patients and caregivers. It is associated with increased morbidity and mortality and earlier placement in long-term care facilities. Existing treatment options are often limited by modest efficacy, tolerability and safety concerns, leaving vast unmet need for therapies that reduce agitation, and improve outcomes without significant adverse effects,” said Anton P. Porsteinsson, M.D., William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine; Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE), University of Rochester School of Medicine and Dentistry. “The results of treatment with NMRA-511 are particularly encouraging, as they demonstrated clinically meaningful effects in agitation symptoms among people with AD agitation, and even more profound results among those with elevated anxiety – representing a significant number of treated patients. These results are particularly compelling given the favorable tolerability profile, and as they are clearly supported by the understood link between the vasopressin system and regulation of anxiety.”

PHASE 1b RESULTS SUMMARY

The Phase 1b study investigated NMRA-511 in healthy elderly adult participants (Part A) as well as people with agitation associated with dementia due to AD (Part B). Part A was a randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability and pharmacokinetics of NMRA-511 in eight healthy elderly participants. Part B was a multicenter, randomized, double-blind, placebo-controlled, parallel-group cohort designed to evaluate the safety, tolerability, and efficacy of NMRA-511 20 mg twice-daily (BID) in 80 people with AD agitation. The Phase 1b study was designed as a signal-seeking study to demonstrate a clinical effect and was not powered for statistical significance.

Key findings from Part B of the Phase 1b study include:

71 patients were included in the efficacy analysis (the modified analysis set [MASi]).36 patients were included in the pre-specified sub-population of patients with elevated anxiety at baseline (Rating Anxiety in Dementia score ≥12).In the MAS, patients treated with NMRA-511 demonstrated a -2.6 and -2.1 placebo-adjusted change from baseline on CMAI total score at Weeks 6 and 8 respectively, representing a Cohen’s d effect size range of 0.20 – 0.23.In the elevated anxiety population, NMRA-511 demonstrated a -7.6 and -5.6 placebo-adjusted change from baseline on CMAI total score at Weeks 6 and 8 respectively, representing a Cohen’s d effect size range of 0.51 – 0.64.NMRA-511 demonstrate a favorable tolerability and safety profile. Treatment emergent adverse events (TEAEs) were typically mild to moderate in severity, and there were low treatment discontinuations due to TEAEs (2.5%). The most common adverse effects (>5% in either treatment group) in the study were nasopharyngitis, urinary tract infection, anemia, arthralgia, diarrhea, dizziness, headache, hyponatremia, myalgia, nausea, vomiting and abdominal pain. NEXT STEPS

Neumora intends to advance the development of NMRA-511. The following next steps are planned for the program:

Initiate a multiple ascending dose extension study investigating higher doses of NMRA-511 in 2026.Formulation development to enable once-daily dosing via an extended-release formulation of NMRA-511 in 2026.Initiate a Phase 2/3 dose ranging study with NMRA-511.
Webcast Information
Neumora will host a conference call at 8:00 a.m. ET on January 5, 2026. Participants can register for the live webcast here. In addition, a replay of the conference call will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About NMRA-511
NMRA-511 is a highly potent and selective, best-in-class investigational antagonist of the vasopressin 1a receptor (V1aR) that exhibited greater than 3,000-fold selectivity over the V1b and V2 receptors and approximately 300-fold selectivity over the oxytocin receptor in preclinical studies. The V1aR is known to play a role in regulation of aggression, affiliation, stress and anxiety response and several lines of evidence, and the Phase 1b data reported today, indicate that V1aR antagonists have therapeutic potential for reducing symptoms of agitation. Based on data available to date, Neumora believes NMRA-511 has the potential to be a promising novel medication for multiple neuropsychiatric disorders and neurodegenerative diseases across the spectrum of anxiety, aggression and stress.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients; NMRA-511’s potential to meaningfully improve agitation symptoms among people with AD agitation and efficacy among patients with higher levels of baseline anxiety and potential differentiation from standard of care; the therapeutic potential of V1aR antagonists for reducing symptoms of agitation; the timing, progress and plans for its therapeutic development programs, including advancement of the development of NMRA-511 ; and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: comparisons to efficacy results from other sponsors should be interpreted with caution due to differences in compounds, study designs, subject characteristics and other factors that may limit direct comparability; the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including contract research organizations; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which was filed with the SEC on November 6, 2025. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements.

Neumora Contact:
Helen Rubinstein
617-402-5700
[email protected]

iModified Analysis Set: 2 placebo patients excluded based on rater change driving outlier data (>3 standard deviations from the mean).

TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to report drill results from hole K-25-287 completed as part of its 2025 program at the Company’s 100% owned Kwanika project in British Columbia. The hole returned higher-grade1 results in both the Pit and Central Zones, highlighted by a significant near-surface intercept of 25.9 metres grading 0.91% Cu and 1.29g/t Au (2.09% copper equivalent2, “CuEq”).

Paul Olmsted, CEO of NorthWest, stated: “This drill hole is the 15th reported from our 2025 exploration program at Kwanika, a program which we believe has been highly successful in achieving its goals and will be value accretive. The program exceeded expectations by demonstrating the continuity of higher-grade zones over significant widths in both the Central Zone and the Pit Zone, materially improving our understanding of the mineralization. Results from the Pit Zone, in particular, are expected to support higher-grade open pit mineral resources. When combined with increased confidence in the higher-grade Central Zone to support alternative underground mining methods, and targeted recovery improvements from ongoing metallurgical test work, we expect to deliver an exciting mineral resource update in the first quarter of the year. Together, these developments are expected to support the potential for a more capital-efficient and economically compelling combined open pit and underground development plan, to be reflected in an updated preliminary economic assessment (“PEA”) delivered in mid 2026 that will aim to improve upon the 2023 PEA3.”

Hole K-25-287 intersected multiple higher-grade intercepts across a number of mineralized zones in both the Pit and Central Zones over significant widths. The hole returned unexpectedly wide intercepts within Pit Zone 10 and 12 at shallow depths, expanding the size of these higher-grade zones and providing better definition of the zones relative to Pit Zone 5.

The hole also intersected the Central Zone over a significant combined true width of 32.0 metres. This result continues to demonstrate the east-west zonation of the mineralization from copper-dominant to gold-dominant towards the west and clarifies an area poorly tested by a historical low-angle drill hole.

Drill Hole Highlights: K-25-287 Pit Zone 11:47.5 metres of 1.22% Cu, 0.82g/t Au (1.99% CuEq) from 96.5 metresPit Zone 10: 35.9 metres of 0.81% Cu, 1.03g/t Au (1.75% CuEq) from 144 metres including 25.9 metres of 0.91% Cu, 1.29g/t Au (2.09% CuEq) from 179.9 metresCentral Zone:32.0 metres of 0.32% Cu, 1.13g/t Au (1.34% CuEq) from 285 metres   Geoff Chinn, VP Business Development and Exploration, added: “With the final drill hole reported in the Kwanika Central Deposit, we have confirmed that potassic alteration crosscut by mineralized quartz stockwork, later deformed by faults and fractures and overprinted by silica, sericite and pyrite, forms discrete continuous zones of higher-grade mineralization. Mineralization at Kwanika is strongly structurally controlled, which we believe has been emplaced along active fault zones. These zones have a distinctive geometry relative to the north-south trending Central Zone, where the Western Zones strike east-west, dip north and abut the western margin of the Central Zone, while the Pit Zones also strike east-west but dip south and abut the eastern margin of the Central Zone. These orientations are consistent with pull-apart faults, where the Central Zone is interpreted to be related to a crossing strike-slip zone, while the Pit Zones and Western Zones are associated with extensional normal faults. Pull-apart extensional faulting is known to be favourable structural settings for porphyry deposits, and while the full extent of structures at Kwanika remains unknown, hidden by younger sedimentary rocks and glacial cover, it represents a highly prospective geological environment warranting further exploration. With drill results at the Kwanika deposit complete we look forward to results from nearby exploration targets drilled as part of the 2025 program.”

Kwanika Exploration Program

On April 10, 2025, NorthWest announced a refined model for its flagship Kwanika project (“Target Model”), highlighting three key higher-grade zones: the Pit, Central and Western Zones. These zones target grades of 1.5% to 2.5% CuEq over combined true thicknesses of 30 to 45 metres, to be assessed against a more selective top-down bulk underground mining method.

The 2025 exploration program was designed to confirm, define and expand on the Company’s understanding of higher-grade copper-gold mineralization within the near surface and underground portions of the current mineral resources. Results of the 15 holes drilled at Kwanika, including holes K-25-287 demonstrate the merits of the program and indicate meaningful progress toward these objectives has been achieved.

The hole location for K-25-287 relative to the entire drill program is presented in Figure 1 below. Figure 2 illustrates the cross section of the position and context of hole K-25-287 relative to the Target Model. Continuous mineralized intercepts and collar locations are summarized in Table 1 and Table 2.

Figure 1: Plan View of 2025 Program Drill Hole Location

Figure 2: Cross Section of Target Model at K-25-287 Drill Location

A summary of the geological aspects of hole K-25-287 is presented below.

The hole was drilled using HQ core at an azimuth of 160° azimuth and a dip of -85° to a depth of 551 metres. Core was half sawn and sampled on 2-metre intervals. The purpose of the hole was to test the eastern extension of the Western Zones and to infill the Pit and Central Zones along the way.

At 26 metres, the hole intersected Pit Zone 5 at a low angle. This intersection confirms and infills the zone, returning a near-surface, gold-dominate mineralized interval over 65 metres (17 metre true width). Mineralization is hosted within strong potassic alteration crosscut by a dismembered early quartz stockwork containing pyrite and chalcopyrite. The interval also returned an elevated 0.11 g/t palladium over its length, indicative of very hot, chloride rich fluids.

At 96.5 metres, the hole intersected Pit Zone 11, confirming and infilling this zone. A near-surface, copper-dominant interval was returned over 48 metres (31 metre true width), hosted within potassic alteration (monzonite) crosscut by a dismembered early quartz stockwork. At 126.7 metres the interval transitions to a propylitic altered diorite with weak overprinting potassic and sericite alteration crosscut by quartz veins and veinlets containing pyrite and chalcopyrite mineralization and anhydrite veins and veinlets.

At 144 metres, the hole intersected Pit Zone 10, confirming and infilling this zone. The hole returned a near-surface interval over 36 metres (23 metre true width), hosted in moderately strong potassic alteration (monzonite) crosscut by quartz veins and veinlets containing pyrite and chalcopyrite mineralization. At 148 metres, the monzonite is strongly tectonized and overprinted by sericite alteration that includes breccias and rubble zones healed by silica, containing well mineralized veins and veinlets containing pyrite and chalcopyrite mineralization.

At 185 metres, the hole intersected Pit Zone 12, confirming and infilling this zone. The hole returned a near-surface interval over 46 metres (29 metre true width), hosted in a propylitic altered diorite overprinted by selective hematite and potassic alteration containing finely disseminated pyrite and vein hosted chalcopyrite and locally bornite mineralization.

At 245 metres, the hole intersected the northern edge of Central Zone 4. The hole returned an interval over 14 metres (9 metre true width), hosted in strong potassic alteration, logged as monzonite, crosscut by a quartz stockwork containing pyrite and chalcopyrite mineralization. The interval also reported an elevated 0.19 g/t palladium over its length indicative of very hot, chloride rich fluids.

At 285 metres, the hole intersected Central Zone 6. The hole returned an interval over 32 metres (21 metre true width), hosted in strong potassic alteration, logged as monzonite, crosscut by a quartz stockwork containing pyrite and chalcopyrite mineralization. Below 299 metres, the rocks transition to a tectonized monzonite overprinted by sericite alteration containing a dismembered quartz stockwork.

The hole did not intersect significant Western Zone mineralization.

Overall, hole K-25-287 demonstrated that the mineralized intersection between the Western and Central Zones does not extend further to the north. However, the hole did return unexpectedly wide intersections of Pit Zone 10 and 12 at shallow depths, defining these moderately southeast dipping zones and illustrating how the steeper dipping Pit Zone 5 branches off these zones.

Table 1: Drill Results in this News Release4 5

HoleFromToLengthZoneCuAuAgCuEqTrue WidthDescription (m)(m)(m) (%)(g/t)(g/t)(%)Est. (m)Target Model Zone ReferenceK-25-28726.091.065.0Pit0.651.123.101.6716.8Higher-Grade Pit Zone 5K-25-28796.5144.047.5Pit1.220.823.001.9930.6Higher-Grade Pit Cu Zone 11K-25-287144.0179.935.9Pit0.811.032.881.7523.0Higher-Grade Pit Zone 10Including154.0179.925.9Pit0.911.293.182.0916.6Higher-Grade Pit Zone 10K-25-287185.3231.045.7Pit0.520.812.421.2729.4Higher-Grade Pit Zone 12K-25-287245.0259.014.0Central0.550.752.441.249.0Higher-Grade Au Zone 4K-25-287285.0317.032.0Central0.321.131.741.3420.6Higher-Grade Au Zone 6            Table 2: Drill Collar Information6

HoleCollar XCollar YCollar ZCollar AzimuthCollar DipFinal LengthK-25-2873514936156310990160-85551        Quality Assurance / Quality Control

Drilling at Kwanika in 2025 was designed and supervised by NorthWest, implemented by InData Geoscience with assay QA/QC checks by Explore Geosolutions. Samples were collected, tracked and an external QA/QC program was implemented using blanks and standards to monitor analytical accuracy and precision. The samples were sealed on site and shipped to Activation Laboratories Ltd. (“Actlabs”) in Kamloops, BC. The laboratory’s internal quality control system complies with global certifications for quality ISO 17025. Drill core samples were analyzed using a combination of Actlabs multi-element 1F2 analysis for low level concentrations (4-Acid Digestion, ICP-OES) and the 8-4 Acid ICP-OES analysis for higher level concentrations (4-Acid Digestion, ICP-OES with automatic over limits for base metals and silver). Gold, platinum and palladium assaying was completed with 1C-OES method, using a 30-gram fire assay with ICP finish analysis. In addition, about 5% of the sample pulps are re-assayed at a secondary laboratory to confirm reproducibility and check for bias.

Amalgamation of Subsidiaries

The Company has completed a vertical short-form amalgamation (the "Amalgamation") with Tsayta Resources Corporation, and 0790202 B.C. Ltd.  (collectively, the "Subsidiaries"), two wholly-owned subsidiaries of the Company, effective January 1, 2026, pursuant to the Business Corporations Act (British Columbia).

The Amalgamation was completed to streamline the financial and regulatory reporting process and reduce administrative costs.

No securities of the Company were issued in connection with the Amalgamation and the Company's share capital remains unchanged. Pursuant to the Amalgamation, all of the issued and outstanding shares of the Subsidiaries were cancelled, and the assets, liabilities and obligations of the Subsidiaries were assumed by the Company. The resulting amalgamated company has retained the name "NorthWest Copper Corp.", maintained the same Articles and management as the Company, and the common shares of the Company remain listed on the TSX Venture Exchange under the symbol "NWST".

The Company has filed the Certificate of Amalgamation and Notice of Articles on SEDAR+, which are publicly available at www.sedarplus.ca.

Technical aspects of this news release have been reviewed, verified, and approved by Geoff Chinn, P.Geo., VP Business Development and Exploration for NorthWest, who is a qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Minerals Projects.

About NorthWest:

NorthWest is a copper-gold exploration and development company with a pipeline of advanced and early-stage projects in British Columbia, including Kwanika-Stardust, Lorraine-Top Cat and East Niv. With a robust portfolio in an established mining jurisdiction, NorthWest is well positioned to participate fully in strengthening global copper and gold markets. The Company is committed to responsible mineral exploration, working collaboratively with First Nations to help ensure future development incorporates stewardship best practices and respects traditional land use. Additional information can be found on the Company’s website at www.northwestcopper.ca.

On Behalf of NorthWest
“Paul Olmsted”
CEO, NorthWest Copper

For further information, please contact: 
416-457-3333
[email protected]  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information 

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to statements with respect to; plans and intentions of the Company; proposed exploration and development of NorthWest’s exploration property interests; the Company’s ability to finance future operations; mine plans; magnitude or quality of mineral deposits; the development, operational and economic results of current and future potential economic studies; adding the Lorraine resource to the Kwanika-Stardust Project; the Company’s goals for 2025; geological interpretations; the estimation of Mineral Resources; anticipated advancement of mineral properties or programs; future exploration prospects; the completion and timing of technical reports; future growth potential of NorthWest; and future development plans.

All statements, other than statements of historical fact, included herein, constitutes forward-looking information. Although NorthWest believes that the expectations reflected in such forward-looking information and/or information are reasonable, undue reliance should not be placed on forward-looking information since NorthWest can give no assurance that such expectations will prove to be correct. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including the risks, uncertainties and other factors identified in NorthWest’s periodic filings with Canadian securities regulators. Forward-looking information are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward-looking information. Important factors that could cause actual results to differ materially from NorthWest’s expectations include risks associated with the business of NorthWest; risks related to reliance on technical information provided by NorthWest; risks related to exploration and potential development of the Company’s mineral properties; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need for cooperation of government agencies and First Nation groups in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; and other risk factors as detailed from time to time and additional risks identified in NorthWest’s filings with Canadian securities regulators on SEDAR+ in Canada (available at www.sedarplus.com). 

Forward-looking information is based on estimates and opinions of management at the date the information is made. NorthWest does not undertake any obligation to update forward-looking information except as required by applicable securities laws. Investors should not place undue reliance on forward-looking information.

__________________

1 “High-grade”, “higher-grade” or “strong intercepts” in this news release means intervals or grades greater than 1.0% CuEq.
2 CuEq assumes metal prices of $2646/oz gold, $4.34/lbs copper, $29.73/oz silver and 80% recovery for all metals, calculated as follows: [Cu+100*((Au/31.1035*Au Price*80%)/(Cu Price*2204.62*80%)+(Ag/31.1035*Ag Price*80%)/(Cu Price*2204.62*80%))]. The New Afton mine was considered as a comparable deposit and reductions to realized recoveries for New Afton were applied for the purpose of Kwanika recoveries.
3 NI 43-101 technical report titled “Kwanika-Stardust Project NI 43-101 Technical Report on Preliminary Economic Assessment” dated February 17, 2023, with an effective date of January 4, 2023, filed under the Company’s SEDAR+ profile at www.sedarplus.com.
4 Estimated true widths based on collar azimuth and dip and the average dip of the mineralized zone
5 CuEq assumes consensus metal prices of $2646/oz gold, $4.34/lbs copper, $29.73/oz silver and 80% recovery for all metals, calculated as follows: [Cu+100*((Au/31.1035*Au Price*80%)/(Cu Price*2204.62*80%)+(Ag/31.1035*Ag Price*80%)/(Cu Price*2204.62*80%))]. The New Afton mine was considered as a comparable deposit and reductions to realized recoveries for New Afton were applied for the purpose of Kwanika recoveries.
6 Collar coordinates reference UTM Zone 10N NAD83.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7e8e3fbe-eb6c-47a8-b3d2-4dad11bacdd6
https://www.globenewswire.com/NewsRoom/AttachmentNg/5f737362-fa1e-4352-8074-4146bf3b090d

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in KR over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

More than $5.5 billion in cryptocurrencies are scheduled to unlock in January, with ONDO, BGB, HYPE, and TRUMP tokens accounting for some of the largest releases this month. 

According to Tokenomist’s token unlocks data tracker, January will see over $5.5 billion in token unlocks. Around $2.5 billion will be released through a cliff unlock, which means the tokens are unlocked all at once. Another $3 billion will enter circulation through linear releases, distributing tokens gradually over time, creating less abrupt supply increases. 

Crypto vesting is the process of locking token allocations and releasing them over time to prevent early or sudden increases in circulating supplies. These schedules often include an initial lockup followed by periodic unlocks, aligning long-term incentives while managing market impact. 

While token unlocks are a routine part of crypto’s vesting mechanics, large releases can sometimes influence price dynamics in the short term, when broader market liquidity is thin or if sentiment is fragile.

Monthly token unlocks from November 2025 to March 2026. Source: TokenomistTop four unlocks account for nearly $2 billion of January’s releasesThe four largest token unlocks for the month include Ondo (ONDO), Bitget Token (BGB), Hyperliquid (HYPE), and Official Trump (TRUMP).

These collectively account for roughly $1.94 billion in incoming supply, representing 35% of the $5.5 billion scheduled to unlock in January.

Ondo leads the group with 1.9 billion tokens unlocking on Jan. 19, worth over $840 million at current market prices. Tokenomist data showed that the release is allocated to the founders, team members, community, and private investors. 

BGB follows with 140 million tokens scheduled to drop on Jan. 26, valued at nearly $500 million. Of the amount, 80 million tokens are allocated to the team, while 60 million will go to branding and promotions.

Hyperliquid will unlock 12.4 million tokens, worth $327 million, on Tuesday for its core contributors, making it the closest unlock in the group. It’s also the third-largest release for the month.

At the time of writing, HYPE traded at $26.41, bagging a 5.7% gain over the past 24 hours. The price data suggests short-term bullish momentum despite the upcoming token release.

Hyperliquid 24-hour price chart. Source: CoinGecko Meanwhile, the official memecoin of US President Donald Trump is scheduled to release 50 million tokens worth $270 million on Jan. 18 for founders and team members. 

Although smaller than ONDO and BGB, both unlocks remain significant given their market profiles and still contribute notable sums to January’s overall supply increase. 

Magazine: Chinese users turn to ‘U cards’ to get around crypto rules: Asia Express

Bitcoin has hit a three-week high as geopolitical tensions escalate once again and analysts predict more gains to come if history rhymes. 

BTC tapped $93,000 during Monday morning in Asia following a strike by the United States on Venezuela over the weekend.

Analysts are now looking for further potential gains and the possibility of a return to six-figure Bitcoin prices. Michael Nadeau from The DeFi Report drew comparisons between the Russian invasion of Ukraine in early 2022, when BTC climbed 22% in the weeks that followed.

“In the current environment, I’ve been anticipating a move for BTC back up to the 50-week moving average around $101,700,” he said. “Now we have a catalyst. The key question is whether that level can hold if it is, in fact, revisited.”

A Bear Market Bounce
What the analyst didn’t mention was the fact that 2022 was a bear market year that saw BTC decline 77% from its all-time high. A similar bear market scenario in 2026 could see the asset slump to $30,000.

Trader Aaron Dishner echoed the sentiment, stating that crypto markets would bounce in early January as many traders likely closed positions before the end of 2025 for tax purposes, and would buy back aggressively at the start of 2026.

“But my target for BTC is still $100k before the next leg down, and I imagine a LOT of you are wondering WHY!? Well, this happens at the start of every past bear market – in 2022, 2018, and 2015. This time is no different to me.”

Bitcoin entrepreneur Joe Consorti was also convinced of a return to six figures first. BTC broke back above the 50-day moving average for the first time since October, testing levels not seen since early December, he said.

“Sell pressure may be nearing exhaustion. Need to reclaim and hold the 50-week MA at $101k.”

BTC is waking up in the new year, already up 6.24%.

Broke back above the 50-day moving average for the first time since October. Testing levels not seen since early December.

Sell pressure may be nearing exhaustion.

Need to reclaim and hold the 50-week MA at $101k. https://t.co/PlgD2IbnWX pic.twitter.com/EJVlVPLN6p

— Joe Consorti (@JoeConsorti) January 5, 2026

Bitcoin Moves Higher
BTC tapped $93,000 twice over the past few hours, but failed to break above, falling back to $92,500 at the time of writing. The asset is now moving towards the upper band of a six-week sideways channel and needs to clear resistance above $94,000 to break out of it.

You may also like:

Bitcoin Gained $3K Since The US Attacked Venezuela but Real Volatility Is Expected Today

Bitcoin Steady at $90K Amid Trump Remarks on Venezuela, Maduro, and Mexico

Bitcoin Drops Below $90K Amid Reports of Explosions in Venezuela

“There is strength beneath this overall bottoming move higher,” said analyst ‘Sykodelic’ who added, “We had the double buy signal on the relative strength two days ago.”

Tags:

Ethereum co‑founder Vitalik Buterin says the latest upgrades give the blockchain high‑bandwidth, consensus‑driven performance. Vitalik Buterin announced that zero‑knowledge Ethereum Virtual Machines have reached production‑quality performance and that PeerDAS data‑availability sampling is live on mainnet, combining to give Ethereum decentralized consensus and high bandwidth.